BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lariccia V, Magi S, Serfilippi T, Toujani M, Gratteri S, Amoroso S. Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. J Clin Med 2020;9:E4021. [PMID: 33322733 DOI: 10.3390/jcm9124021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Zoulikha M, Huang F, Wu Z, He W. COVID-19 inflammation and implications in drug delivery. J Control Release 2022;346:260-74. [PMID: 35469984 DOI: 10.1016/j.jconrel.2022.04.027] [Reference Citation Analysis]
2 Farmani AR, Mahdavinezhad F, Scagnolari C, Kouhestani M, Mohammadi S, Ai J, Shoormeij MH, Rezaei N. An overview on tumor treating fields (TTFields) technology as a new potential subsidiary biophysical treatment for COVID-19. Drug Deliv Transl Res 2021. [PMID: 34542840 DOI: 10.1007/s13346-021-01067-5] [Reference Citation Analysis]
3 Papakonstantinou E, Pierouli K, Mitsis T, Diakou KI, Palaiogeorgou A, Bacopoulou F, Chrousos G, Eliopoulos E, Vlachakis D. COVID‑19 global social lockdowns: Energy‑related, psychological, epigenetic, health and environmental impacts (Review). Int J Epigen 2021;1. [DOI: 10.3892/ije.2021.8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Taher A, Lashgari M, Sedighi L, Rahimi-Bashar F, Poorolajal J, Mehrpooya M. A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. Pharmacol Rep 2021. [PMID: 34114174 DOI: 10.1007/s43440-021-00296-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Sauter D, Kirchhoff F. Evolutionary conflicts and adverse effects of antiviral factors. Elife 2021;10:e65243. [PMID: 33450175 DOI: 10.7554/eLife.65243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]